Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study. - Atas Ipek S; Yaslikaya S; Kara IO; Koseci T; Bayram E; Asarkaya E; Asoglu H; Turker M; Aykut A; Jeral Evinc S; Alan O; Yilmaz ME; et al. (Journal of clinical medicine, 2026)